Ropinirole in the treatment of Parkinson’s disease
- 1 May 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 8 (5) , 697-710
- https://doi.org/10.1517/13543784.8.5.697
Abstract
In this review, the pharmacokinetics, safety and tolerability, and clinical efficacy of ropinirole (Requip), a non-ergoline dopamine agonist approved for use in the treatment of Parkinson's disease (PD) are examined. A summary of preclinical and clinical studies is presented. Ropinirole is safe and efficacious as monotherapy in the treatment of early PD and as an adjunct to levodopa in more advanced cases.Keywords
This publication has 30 references indexed in Scilit:
- Ropinirole for the Treatment of Early Parkinson Disease: A 12-Month ExperienceArchives of Neurology, 1998
- Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year studyMovement Disorders, 1998
- Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled studyMovement Disorders, 1998
- Ropinirole for the treatment of early Parkinson's diseaseNeurology, 1997
- Ropinirole in the Treatment of Levodopa-Induced Motor Fluctuations in Patients with Parkinson's DiseaseClinical Neuropharmacology, 1996
- Comparative Review of Dopamine Receptor Agonists in Parkinsonʼs DiseaseCNS Drugs, 1996
- Subtypes and localization of dopamine receptors in human brainNeurochemistry International, 1993
- Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Ropinirole without levodopa in Parkinson's diseaseThe Lancet, 1990
- Effects of ergots on adenylate cyclase activity in the corpus striatum and pituitaryLife Sciences, 1977